stockrow
Saturday 7 November 2026
Export CRBU’s income statement to Excel — free account
Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024.
- Revenue
- −26.9%
- EPS
- +16.7%
- Free cash flow
- +84.8%
Quarter to September 2026, against a year earlier
0.44
0.03
+7.32%
Follow CRBU
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.46 | 17.71 | 16.26 | 13.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.06) | (7.80) | (6.75) | (7.13) | |
P/B ratio |
1.78 | 1.81 | 1.79 | 1.22 | |
Price to Tangible BV |
1.78 | 1.81 | 1.79 | 1.22 | |
EV/Sales |
4.42 | 6.52 | 5.76 | 0.82 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.45) | (0.68) | (0.64) | (0.08) | |
EV/FCF |
(0.32) | (0.49) | (0.63) | (0.08) | |
Quick Ratio |
4.71 | 6.32 | 6.06 | 5.56 | |
Current Ratio |
4.97 | 6.49 | 6.22 | 5.71 | |
Net Debt/EBITDA |
3.48 | 4.54 | 4.54 | 4.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.06 | 0.05 | 0.05 | |
Operating CF/Net income |
0.85 | 0.94 | 1.08 | 0.79 | |
Capex/Depreciation |
0.00 | 147.31 | (0.19) | 0.41 | |
Research and Development Expense of Revenue |
1,328.50% | 1,263.64% | 859.87% | 604.29% | |
Selling, General and Administrative Expense of Revenue |
491.60% | 526.75% | 336.50% | 217.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
134.60% | 165.24% | 98.33% | 69.47% | |
Graham Net Nets |
0.39 | 0.40 | 0.41 | 0.62 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(81.10%) | (61.36%) | (74.74%) | (100.00%) | |
Free Cash Flow Yield |
(95.28%) | (74.71%) | (55.80%) | (75.66%) | |
Revenue per Share |
0.01 | 0.01 | 0.03 | 0.04 | |
Operating CF per Share |
(0.21) | (0.23) | (0.28) | (0.22) | |
Capex per Share |
0.00 | 0.85 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | 0.62 | (0.28) | (0.22) | |
Cash per Share |
0.88 | 1.11 | 1.23 | 1.49 | |
Shareholders Equity per Share |
0.71 | 0.97 | 1.06 | 1.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.71 | 0.97 | 1.06 | 1.31 | |
Free Cash Flow |
(22.52) | 62.80 | (27.06) | (20.61) | |
Working Capital |
79.93 | 98.62 | 102.71 | 119.82 | |
Capital Expenditures |
— | 85.59 | (0.07) | 0.22 | |
Net Current Asset Value |
53.68 | 71.92 | 75.40 | 92.04 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (57.10) | 0.03 | (0.05) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 1.68 | 1.80 | 2.03 | |
Average Payables |
4.43 | 3.16 | 3.69 | 4.13 | |
Average Assets |
159.01 | 181.84 | 211.33 | 244.34 | |
Average Common Equity |
109.24 | 132.12 | 159.62 | 187.56 |
Columns are period end dates · fundamentals updated 5 Nov 2026